Compounds > 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
Page last updated: 2024-11-13
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
Description
## 1-Palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC)
**1-Palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC)** is a synthetic phospholipid. It's essentially a modified version of a naturally occurring phospholipid, phosphatidylcholine (PC).
**Structure:**
* **Palmitoyl (C16:0):** A saturated fatty acid chain with 16 carbon atoms.
* **Azelaoyl (C9:0):** A saturated fatty acid chain with 9 carbon atoms.
* **sn-Glycero-3-phosphocholine:** The backbone of the phospholipid, including the glycerol molecule and the choline head group.
**Importance in Research:**
PAzePC is particularly important for research in several areas:
1. **Lipid Metabolism & Signaling:**
* PAzePC is a valuable tool for studying lipid metabolism and signaling pathways. By incorporating it into model systems, researchers can analyze how different lipids interact with cellular processes.
* It can be used to investigate the role of specific lipids in various cellular functions, such as membrane fluidity, cell signaling, and enzyme activity.
2. **Membrane Structure & Function:**
* PAzePC can be incorporated into artificial membranes, like liposomes. This allows researchers to study how different lipids affect membrane properties and function.
* By varying the fatty acid composition of PAzePC, researchers can explore the relationship between lipid structure and membrane properties like permeability, fluidity, and stability.
3. **Drug Delivery & Nanomedicine:**
* PAzePC is used to design and develop new drug delivery systems. Its unique properties make it suitable for encapsulating various drugs and delivering them to specific targets within the body.
* Researchers are investigating the use of PAzePC-based liposomes to improve the efficiency and safety of drug delivery.
4. **Biomaterials and Tissue Engineering:**
* PAzePC is being explored for its potential in creating biocompatible materials for tissue engineering applications. Its biodegradability and biocompatibility make it suitable for constructing scaffolds for tissue regeneration.
* It can be used to mimic the natural environment of cells, fostering their growth and differentiation.
**In summary:**
PAzePC is a versatile synthetic phospholipid with several applications in research, including lipid metabolism, membrane studies, drug delivery, and biomaterials. Its ability to mimic natural lipids while offering specific structural modifications makes it a valuable tool for understanding complex biological processes and developing new therapeutic strategies.
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and azelaoyl groups at positions 1 and 2 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 46907870 |
CHEBI ID | 61817 |
SCHEMBL ID | 22607965 |
MeSH ID | M0520995 |
Synonyms (28)
Synonym |
pc(16:0/9:0(cooh)) |
1-hexadecanoyl-2-(9-carboxy-nonanoyl)-sn-glycero-3-phosphocholine |
LMGP20010007 |
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine |
2-o-azelaoyl-1-o-palmitoyl-sn-glycero-3-phosphocholine |
16:0-09:0(aldo)pc |
CHEBI:61817 , |
1-o-palmitoyl-2-o-azelaoyl-sn-glycero-3-phosphocholine |
(2r)-2-[(8-carboxyoctanoyl)oxy]-3-(palmitoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate |
16:0-09:0(aldo)phosphocholine |
EPITOPE ID:153523 |
gtpl5427 |
azelaoyl pc |
paz-pc |
(2-{[(2r)-2-[(8-carboxyoctanoyl)oxy]-3-(hexadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium |
1-palmitoyl-2-azelaoyl pc |
GHQQYDSARXURNG-SSEXGKCCSA-N |
1-o-hexadecanoyl-2-o-(9-carboxyoctanoyl)-sn-glyceryl-3-phosphocholine |
HMS3649G17 |
J-003538 |
pazepc, 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine, chloroform |
pazepc, 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine, powder |
2-[(8-carboxyoctanoyl)oxy]-3-(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate |
DTXSID20922533 |
Q27088247 |
[(2r)-2-(8-carboxyoctanoyloxy)-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
SCHEMBL22607965 |
AKOS040754953 |
Drug Classes (1)
Class | Description |
1,2-diacyl-sn-glycero-3-phosphocholine | The conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 13 (81.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.09 (24.57) | Research Supply Index | 2.83 (2.92) | Research Growth Index | 4.92 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |